News | August 30, 2022
Thermo Fisher Scientific present new innovations to improve biopharmaceutical and proteomics workflows
New mass spectrometry instrument and consumables launch during IMSC 2022
New mass spectrometry instrument and consumables launch during IMSC 2022
With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies
_256_384.png)
Thermo Scientific Direct Mass Technology mode augments Thermo Scientific Q Exactive UHMR Hybrid Quadrupole-Orbitrap mass spectrometers with charge detection capabilities
Co-marketing agreement between Thermo Fisher Scientific and TransMIT allows for high spatial and high mass resolution MSI platform to study complex biological tissues
This facility will design & develop instruments, perform product reliability performance testing and verification
The $44 million facility is part of Thermo Fisher's $650 million multi-year investment, announced last year, to help ensure flexible, scalable and reliable bioprocessing production capacity exists for critical materials used in developing new and existing biologics and vaccines, including for COVID-19
The business is a recognized leader in managing Covid-19 and mRNA research programs
It supports advanced research and helps scientists accelerate potential cures, drug discoveries and diagnostics research
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
Expanding the Applied Biosystems portfolio with the latest generation of innovative, mid-throughput genetic analyzers
Subscribe To Our Newsletter & Stay Updated
